Castleark Management LLC Sells 990 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Castleark Management LLC lowered its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 3.5% in the 3rd quarter, Holdings Channel.com reports. The fund owned 27,290 shares of the company’s stock after selling 990 shares during the period. Castleark Management LLC’s holdings in Krystal Biotech were worth $4,968,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. EFG Asset Management North America Corp. lifted its position in shares of Krystal Biotech by 0.5% in the 2nd quarter. EFG Asset Management North America Corp. now owns 12,555 shares of the company’s stock worth $2,308,000 after purchasing an additional 60 shares during the period. GAMMA Investing LLC lifted its holdings in Krystal Biotech by 160.3% in the second quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock valued at $28,000 after buying an additional 93 shares during the period. Nisa Investment Advisors LLC boosted its position in Krystal Biotech by 11.1% during the second quarter. Nisa Investment Advisors LLC now owns 940 shares of the company’s stock valued at $173,000 after acquiring an additional 94 shares during the last quarter. Arizona State Retirement System boosted its position in Krystal Biotech by 2.1% during the second quarter. Arizona State Retirement System now owns 5,147 shares of the company’s stock valued at $945,000 after acquiring an additional 108 shares during the last quarter. Finally, Fiera Capital Corp grew its holdings in Krystal Biotech by 0.8% during the 2nd quarter. Fiera Capital Corp now owns 16,208 shares of the company’s stock worth $2,976,000 after acquiring an additional 130 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Trading Up 3.1 %

Krystal Biotech stock opened at $185.25 on Friday. The firm has a market capitalization of $5.33 billion, a price-to-earnings ratio of 104.66 and a beta of 0.80. The firm’s fifty day moving average price is $181.27 and its two-hundred day moving average price is $184.52. Krystal Biotech, Inc. has a 1-year low of $101.34 and a 1-year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.07. The business had revenue of $83.84 million for the quarter, compared to analysts’ expectations of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The firm’s revenue for the quarter was up 879.9% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.67) EPS. On average, research analysts forecast that Krystal Biotech, Inc. will post 2.97 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on KRYS. Cantor Fitzgerald restated an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. Evercore ISI raised their price objective on shares of Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a research report on Monday, August 12th. HC Wainwright reiterated a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a research report on Tuesday, November 5th. Stifel Nicolaus raised their price target on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. Finally, Citigroup lifted their price target on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $202.29.

Insider Activity

In related news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the sale, the insider now owns 1,500,882 shares in the company, valued at approximately $296,814,424.32. This represents a 1.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 14.10% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).